Who is the CEO of BioPlus?

According to the DART company overview, BioPlus' representative director is 정현규 (name as registered in Korean). The company was founded on 2003-05-23.

Where is BioPlus listed?

BioPlus trades on the Korea Exchange KOSDAQ market under the ticker 099430. Its fiscal year ends in December.

Does BioPlus pay a dividend?

Yes. For fiscal 2025, BioPlus paid a cash dividend of ₩70 per common share, a 1.4% yield as stated in its annual report, with a payout ratio of 28.7%. The prior year's dividend was ₩50.

Does BioPlus have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn); Major holder adding (a 5%+ shareholder reported raising its stake (30 days)). These are factual flags, not investment advice.

Which companies are in the same industry as BioPlus?

Under the Korean Standard Industrial Classification recorded on DART, BioPlus is grouped with 44 other listed companies in pharmaceutical ingredients. The most covered in Korean news over the past 30 days are Celltrion, Samsung Biologics and Peptron.

BioPlus KRX:099430KOSDAQ

바이오플러스 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h1

Articles, 7 days15

DART filings, 7 days0

Articles tracked25since Sep 11

In Q2 2026, BioPlus reported revenue of ₩25.4bn, up 22.9% year on year, and operating profit of ₩6.2bn. BioPlus (바이오플러스) appeared in 15 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 28 with 12 articles. The most common catalyst was policy & overseas (1). It was most often mentioned alongside 글로벌테크놀로지 and Samsung Biologics.

Filing signals Profit +50% Revenue & profit growth Op. margin 20%+ Major holder adding Screener

BioPlus quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩25.4bn	+22.9%	₩6.2bn margin 24.6%	₩3.7bn
Q1 2026	₩26.5bn	+15.4%	₩5.7bn margin 21.3%	₩8.0bn
Q4 2025 derived	₩23.2bn	-20.3%	₩963m margin 4.2%	₩3.6bn
Q3 2025	₩24.1bn	+46.5%	₩4.9bn margin 20.3%	₩4.4bn
Q2 2025	₩20.7bn	+83.1%	₩2.1bn margin 10.0%	₩3.4bn
Q1 2025	₩23.0bn	+139.1%	₩7.1bn margin 30.9%	₩8.5bn
Q4 2024 derived	₩29.1bn	+80.0%	₩13.8bn margin 47.5%	₩4.5bn
Q3 2024	₩16.4bn	-6.3%	₩4.7bn margin 28.7%	₩4.1bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

BioPlus top stories 2 weeks, by number of outlets

1
바이오플러스-인터펙스 코리아 개막…300여개 기업 참여
5 outlets · 5 articlesFirst report Oct 28 06:00 연합뉴스경제
2
[포토] 삼성바이오로직스, ‘바이오플러스-인터펙스 코리아 2026’ 참가
1 outlets · 2 articlesFirst report Oct 29 14:13 이뉴스투데이Samsung Biologics
3
“AI 기반 신약개발 전략 공유”…바이오플러스 2026 개막
1 outlets · 1 articlesFirst report Oct 28 17:07 디지털타임스
4
‘바이오플러스-인터펙스 코리아 2026’ 개막…방사성의약품 글로벌 진출 전략 조명
1 outlets · 1 articlesFirst report Oct 28 15:10 글로벌이코노믹Overseas expansion글로벌테크놀로지
5
바이오플러스-인터펙스 코리아 개막⋯고한승 바이오협회장 “우연을 필연으로 만드는 장소”
1 outlets · 1 articlesFirst report Oct 28 12:03 코메디닷컴
6
“좋은 제품, 힘들게 고르지 마세요”… 깐깐한 기준 내세운 커머스 ‘두들’ / 프리다 칼로의 고통부터 ‘죽은 자들의 날’ 축제까지⋯ / 바이오플러스-인터펙스 코리아 개막⋯고한승 바이오협회장 “우연을 필연으로 만드는 장소”
1 outlets · 1 articlesFirst report Oct 29 06:00 코메디닷컴

Latest BioPlus news Korean headlines

Oct 2914:13
[포토] 삼성바이오로직스, ‘바이오플러스-인터펙스 코리아 2026’ 참가
이뉴스투데이Samsung Biologics
1 more on this story · 1 outlets
- [포토] 바이오플러스-인터펙스 코리아 2026이뉴스투데이 · Oct 29 15:57
Oct 2906:00

“좋은 제품, 힘들게 고르지 마세요”… 깐깐한 기준 내세운 커머스 ‘두들’ / 프리다 칼로의 고통부터 ‘죽은 자들의 날’ 축제까지⋯ / 바이오플러스-인터펙스 코리아 개막⋯고한승 바이오협회장 “우연을 필연으로 만드는 장소”
코메디닷컴
Oct 2817:07

“AI 기반 신약개발 전략 공유”…바이오플러스 2026 개막
디지털타임스
Oct 2815:46

'바이오플러스-인터펙스 코리아 2026' 개막..."고난의 시기 극복 전략 모색"
메트로신문
Oct 2815:10

‘바이오플러스-인터펙스 코리아 2026’ 개막…방사성의약품 글로벌 진출 전략 조명
글로벌이코노믹Overseas expansion글로벌테크놀로지
Oct 2813:42

바이오플러스-인터펙스 코리아 개막…글로벌 바이오기업 300곳 모였다
뉴스웍스글로벌테크놀로지
Oct 2812:03

바이오플러스-인터펙스 코리아 개막⋯고한승 바이오협회장 “우연을 필연으로 만드는 장소”
코메디닷컴
Oct 2809:13

바이오기업 300여곳 서울 집결…'바이오플러스 2026' 개막
스페셜경제
Oct 2806:00
바이오플러스-인터펙스 코리아 개막…300여개 기업 참여
연합뉴스경제
4 more on this story · 4 outlets
- 바이오플러스-인터펙스 코리아 개막…300여개 기업 참여한민족센터 · Oct 28 06:06
- 바이오플러스-인터펙스 코리아 개막…론자 등 300여개 기업 참여헤럴드경제 · Oct 28 11:08
- [AT 포토] 바이오플러스-인터펙스 코리아 개막…300여개 기업 한자리에아시아타임즈 · Oct 28 13:56
- [포토] '바이오플러스-인터펙스 코리아 2026' 개막세계일보 · Oct 28 15:24
Oct 2806:00

국내외 바이오기업 300곳 집결…'바이오플러스' 개막
뉴시스경제
Oct 2111:15

비티젠, 바이오플러스-인터펙스 코리아 2026(BIX 2026)’ 참가
디스커버리뉴스
Oct 1509:12
바이오플러스, 브라질 3대 제약사 시메드와 필러 신제품 공식 론칭
더바이오
1 more on this story · 1 outlets
- 바이오플러스, 브라질 시메드와 필러 신제품 론칭머니투데이 · Oct 15 11:55
Oct 1217:43

오토닉스, 바이오플러스-인터펙스 코리아 2026서 바이오·제약 제조 데이터 관리 솔루션 공개
헬로티
Oct 208:36

‘바이오플러스-인터펙스 코리아’ 개최 한달 앞… 전체 컨퍼런스 일정 공개
매일일보
Sep 2810:54

바이오플러스, ‘HUGRO 콜라겐’ 국제 화장품 원료명(INCI) 등재
팜뉴스
Sep 2810:52

바이오플러스, ‘HUGRO 콜라겐’ 적용 재조합 인간형 콜라겐 타입Ⅲ INCI 등재
더바이오
Sep 2311:06

바이오플러스, DVS 가교 기술 기반 HA 필러 개발…MDM® 제조 공정 적용
바이오타임즈
Sep 1520:28

바이오플러스, '휴그로' 성장인자 기반 화장품 원료 및 BMTS 적용
머니투데이
Sep 1116:24

[뷰티 강소주 조명] 바이오플러스, 에스테틱 외연 확장…수익성 관건
블로터

Articles per day 2 weeks

121

1228

329

Company profile

CEO: 정현규
Industry: Pharmaceutical ingredients
Founded: 2003-05-23
Fiscal year-end: December
Head office: 경기도 성남시
Website: bioplus.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

BioPlus dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩70	1.4%	28.7%
FY2024	₩50	0.7%	20.6%
FY2023	₩70	1.0%	16.4%

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

정현규29.82%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Pharmaceutical ingredients

All in industry

Company	Latest quarter op. profit	Articles 30d
Celltrion	₩452bn	968
Samsung Biologics	₩586bn	380
Peptron	−₩7.9bn	103
SK Bioscience	−₩15.7bn	90
ABL Bio	−₩16.8bn	69
Medy-Tox	₩4.8bn	64
Hugel	₩56.0bn	47
Shaperon	−₩3.1bn	39

Compare BioPlus side by side with these companies

BioPlus DART filings

Oct 815:29

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports

Catalysts 2 weeks

Policy & overseas1

Mentioned alongside 2 weeks

BioPlus FAQ

Who is the CEO of BioPlus?: According to the DART company overview, BioPlus' representative director is 정현규 (name as registered in Korean). The company was founded on 2003-05-23.
Where is BioPlus listed?: BioPlus trades on the Korea Exchange KOSDAQ market under the ticker 099430. Its fiscal year ends in December.
What were BioPlus' latest quarterly results?: In Q2 2026, BioPlus reported revenue of ₩25.4bn, up 22.9% year on year, and operating profit of ₩6.2bn. Figures come from reports filed on DART.
Does BioPlus pay a dividend?: Yes. For fiscal 2025, BioPlus paid a cash dividend of ₩70 per common share, a 1.4% yield as stated in its annual report, with a payout ratio of 28.7%. The prior year's dividend was ₩50.
Does BioPlus have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn); Major holder adding (a 5%+ shareholder reported raising its stake (30 days)). These are factual flags, not investment advice.
Which companies are in the same industry as BioPlus?: Under the Korean Standard Industrial Classification recorded on DART, BioPlus is grouped with 44 other listed companies in pharmaceutical ingredients. The most covered in Korean news over the past 30 days are Celltrion, Samsung Biologics and Peptron.